Skip Main Navigation
Page Content
This event has ended

Save This Event

Event Saved

Danish Innovation for Canadian Healthcare

MaRS and the Royal Danish Consulate

Thursday, September 18, 2014 from 10:00 AM to 2:00 PM (PDT)

Registration Information

Type End Quantity
Please note that space may no longer be avaliable for the lunch portion of the event; however, registration remains open for the Seminar from 10.00 - 12.00
Ended Free  

Event Details



VENUE:MaRS Discovery District,Auditorium, 101 College Street, Toronto
DATE: Thursday, September 18th, 2014
TIMING:Program runs 10:00–14:00

Throughout the world, governments are facing a similar challenge: how can we provide increasingly sophisticated healthcare to a population that lives longer, suffers from an increasing number of chronic illnesses, and expects easy access to treatment with limited resources? 

Throughout the world, governments are facing a similar challenge: how can we provide increasingly sophisticated healthcare to a population that lives longer, suffers from an increasing number of chronic illnesses, and expects easy access to treatment with limited resources? 

Denmark has managed to increase public satisfaction with healthcare services, as well as improve productivity and quality, while successfully keeping health expenditures in check. Denmark has accomplished this by putting the patient at the centre of the system, which is supported through the use of technology and a focus on design and quality. Moreover, through the involvement of patients and close public-private cooperation, Danish healthcare companies have been key players in ensuring cost-efficient healthcare.

Over 15 companies are participating in the health delegation and keen to explore opportunities in the Canadian market. For further information please visit: 


10:30 WELCOME AND SETTING THE CONTEXT FOR COLLABORATION (moderator: Earl Miller, Director Partnerships, MaRS)

  • Adopting Valuable Health Innovations in Canada: Shall the Last be the First? (Fiona A. Miller, Associate Professor of Health Policy, University of Toronto)
  • Danish Healthcare: Context and Opportunities (Hans Erik Henrikson, CEO Healthcare DENMARK)

10:55 PANEL: ACCESSING THE CANADIAN MARKET (moderator: Zayna Khayat, Senior Advisor, Health System Innovation and Director,MaRS EXCITE) 

  • Kenneth P.H. Pritzker, President and CEO, RNA Diagnostics Inc.
  • Henrik Brandborg, President and CEO, Radiometer North America
  • Peter Pichini, VP and General Manager, Coloplast Canada 
  • Tom Reeves,CEO and President, Interface Biologics

(moderator: Neil Fraser, President, Medtronic of Canada Ltd.))

  • Jens Peter Bredholdt, CEO Kapacitet
  • Svend-Erik Jensen, Sales Manager, SP Medical
  • Dan Boyter, Executive Vice President, Pressalit
  • Henrik Ibsen, CEO, Silverbullet
  • Anders Fogstrup, Country Manager, Norpharma

Welcome (Karen Greve Young, VP, Partnerships, MaRS Discovery District)
Networking by Zone: 

  • Biotechnology and Pharmaceuticals (moderator: Vice President and General Manager, Celgene Inc., Mr. Kevin Leshuk)
  • Medical Devices and Diagnostics (moderator: Peter Goodhand, Board Chair, HTX)
  • Health IT (moderator: Jennifer Zelmer, Executive Vice President, Canada Health Infoway)
  • Social Entrepreneurship: (moderator: Jessica Ching, Co-Founder and CEO, Eve Medical)



Jens Peter Bredholt
Jens Peter Bredholt is the co-founder/-owner and CEO of Kapacitet A/S, an innovative Danish engineering company located in Copenhagen, Denmark. The company has specialized in technology and product development of medical devices, rehab products and other advanced high quality products. The development process starts from the early ideas, concepts or needs all the way to a working prototype and 0-series production of the product. The approach to product development is focused on an operational hands-on approach including in-house facilities for prototyping and tests ensuring a fast track to the market. The company often work as an agile complementary task force unit in close co-operation with the existing R&D department of the client. The team consist of 20+ very dedicated people and mainly engineers (M.Sc./B.Sc. ME), all with a practical skilled background and production knowledge as toolmakers, precision mechanics and fine smiths. 


Jessica Ching, Co-Founder and CEO, Eve Medical
Jessica Ching is an industrial designer responsible for product development and the overall direction of Eve Medical. She has worked previously in product development and manufacturing liaison roles for Herman Miller, Umbra and Telus. She is a graduate of OCAD University, and also holds a BA in International Development from McGill University. 


Neil Fraser, President,  Medtronic of Canada Ltd.
Neil Fraser joined Medtronic of Canada Ltd. in 1984 and was promoted to President in 2004. Under Neil’s leadership, Canada has led the global corporation in business model innovation, market position, productivity and efficiency, and employee engagement in a challenging healthcare environment. Medtronic of Canada is honoured to receive numerous awards including: Great Place to Work Top 50, Top 100 Employer in Canada, Top Employer in the GTA, and LEED Silver Certification
Neil is passionate about shaping the Canadian medical technology market environment and driving an innovation agenda that will result in better health care for Canadians. In 2013, Neil was appointed Council Member, Ontario Health Innovation Council at the Ontario Ministry of Health and Long-Term Care and also became a Member of the Advisory Board for the Life Sciences Division of the National Research Council Canada. Neil is also Chair of the Ivey International Centre for Health Innovation Advisory Council, an executive board member of Medical Device Canada (MEDEC), and is a founding member and co-chair of the Centre for the Advancement of Health Innovations (CAHI) at the Conference Board of Canada. 


Peter Goodhand, Board Chair, HTX
Peter Goodhand is a leader in the global health sector as a senior executive and board member in the health research advancement community. Goodhand played a key role in the creation of the global alliance to accelerate progress in genomic research and medicine and in June 2013, he was appointed acting Executive Director of the Alliance for its critical development phase.
Prior to this role, he was the President and CEO of the Canadian Cancer Society - Canada’s largest health charity. Before joining the charitable sector, Goodhand had a 20 year career in the global medical technology industry, including strategic leadership roles with multinational healthcare companies such as American Cyanamid and Johnson & Johnson and as the founding Managing Director of the Health Technology Exchange (HTX)

He is currently Chair of the Board of HTX; Chair of the Steering Committee of the Occupational Cancer Research Center; Board Member, MaRS EXCITE (Excellence in Clinical Innovation and Technology Evaluation); and works with the Institute of Corporate Directors to advance governance within the not-for -profit sector.

He served as board Chair and President of Canada’s Medical Device Industry association (MEDEC), chaired the Government of Canada’s Expert working group on the future of medical isotope production, and was a member of the Canadian delegation to the UN summit on non-communicable diseases.
Goodhand had a 12-year experience as a patient advocate, caregiver and navigator throughout his family’s battle with a rare cancer.

Hans Erik Henriksen
Hans Erik Henriksen is CEO of Healthcare DENMARK. Healthcare DENMARK is a publicprivate partnership organization, with a national mandate to promote Danish healthcare solutions and competencies abroad. The partnership is a framework for linking international partners with efficient Danish solutions and does not represent individual companies.

He has a solid healthcare background from different executive positions during the latest 20 years. He was CEO of the innovative Danish healthcare-IT company Cetrea, which during 2008-2012 was established as a leading provider of solutions to the Danish market and during the same period accessed markets in other Nordic countries, Germany, Netherlands and USA.
Before joining Cetrea, he was responsible for IBM Healthcare and Life Sciences in the Northern and Eastern part of Europe (the countries U.K., Ireland, South Africa, Germany, Austria, Switzerland, the Nordic Countries and Central and Eastern Europe).

Since 2008 he has also been engaged as board member in a number of different healthcare and healthcare-IT companies. During 2012 he was a member of the Danish Governments Growth team for Healthcare and welfare solutions.

Zayna Khayat, Senior Advisor, Health System Innovation and Director, MaRS EXCITE
Zayna Khayat is a senior advisor in health systems innovation at MaRS and director of the MaRS EXCITE program. She plays a critical role in helping MaRS clients to get their innovations adopted by healthcare systems in Ontario and around the world. Zayna was previously director of development at the Ivey International Centre for Health Innovation, where she is also currently an adjunct faculty member. Prior to her time at Ivey, Zayna had an 11-year career in strategy consulting in the global health and life sciences sector, first with the Boston Consulting Group’s Toronto office from 2001 to 2010, and then as an associate principal with SECOR Consulting (acquired by KPMG in 2012).

Zayna is also an adjunct professor in the Health Sector Strategy stream at the University of Toronto’s Rotman School of Management, as well as a senior advisor on Rotman’s Health Leadership Advisory Board. She holds a PhD in biochemistry from the University of Toronto and the Hospital for Sick Children, with a focus on insulin action and diabetes. She lives in Toronto with her husband and three children.


Kevin Leshuk, Vice President and General Manager, Celgene Inc.
Kevin Leshuk began his career in the pharmaceutical/biotech industry in the early 1990’s with AdriaOncology. He is presently the Canadian General Manager for Celgene; a multinational biopharmaceutical company focused on the discovery, development and commercialization of products for the treatment of cancer and other severe, immune-inflammatory conditions. Through his career, Kevin has had the tremendous good fortune to work within some of the leading Canadian pharmaceutical companies that have provided the opportunity to work in multiple therapeutic areas. Over the past 20 years, Kevin has held management and senior management roles with specific responsibilities in Sales, Marketing, Key Account Management and most recently Market Access.


Earl Miller, Director, Partnerships – Government and International Relations
Earl Miller is the Director, Partnerships – Government and International Relations. He leads MaRS’ Regional Innovation Centre and is responsible for provincial commercialization relationships,  government stakeholders in the Toronto Region and business development with Canadian trade and economic development officials, foreign governments and international partners. He collaborates with organizations in the public and private sectors looking to source new technology, invest in startup companies and undertake projects to share knowledge about innovation best practices. Earl has master’s degrees in political science and environmental studies, and is an accredited partnership broker. Prior to joining MaRS, he worked at senior levels in the Ontario Public Service, and at Scotiabank and Ryerson University. 

Fiona Miller, Associate Professor of Health Policy, University of Toronto
Fiona A. Miller (PhD) is an Associate Professor of Health Policy in the Institute of Health Policy, Management and Evaluation and heads the Division of Health Policy and Ethics at the Toronto Health Economics and Technology Assessment (THETA) Collaborative at the University of Toronto. Her program of research is concerned with health research and innovation systems and health technology policy, with recent work on health technology assessment and adoption. 

Peter Pichini, General Manager, Coloplast Canada
Peter Pichini has recently been appointed as General Manager for Coloplast Canada.  Previous to this position at Coloplast, Peter was a leader in management roles for over 10 years, most recently as Business Unit Director for the Wound and Skin Care organization.  Prior to joining Coloplast,  he worked in the pharmaceutical industry for over 20 years with GlaxoSmithkline and Bayer, progressing in leadership roles within the marketing and sales function gaining extensive experience in strategic planning, product launches, mergers & acquisitions and team development. Peter has and continues to serve on a range of committees in Rx&D and MEDEC. Peter received his BSc degree at the University of Waterloo.  He also completed the Executive Leadership Program at the London Business School as well as at the University of Notre Dame - Mendoza College of Business.

Dr. Ken Pritzker, President and CEO, Rna Diagnostics Inc.
Dr. Ken Pritzker is President and CEO, Rna Diagnostics  Inc., a company which is developing and bringing to market the RNA Disruption Assay (RDA™),a personalized medicine  molecular test to determine whether or not breast cancer chemotherapy is working effectively in individual patients.

Prior to Rna Diagnostics, Dr. Pritzker served as Chief, Pathology and Laboratory Medicine, at Mount Sinai Hospital in Toronto from 1986 to 2008, and subsequently as founder of Mount Sinai Services, a laboratory service outreach vehicle for the biomedical research and innovation sector. As well, Dr. Pritzker is Professor in the Departments of Laboratory Medicine and Pathobiology; Surgery at the University of Toronto. With over 250 scientific publications, Ken is a recognized leader internationally in the fields of arthritis, biomaterials, genomics, cancer diagnostics and nanotechnology.

Throughout his career, Ken has served in leadership and advisory positions to national and international professional societies, research institutes, healthcare organizations and healthcare companies. Dr. Pritzker is widely recognized for advancing personalized medicine through innovation-based, patient-centered clinical laboratory practice.

Tom Reeves
Thomas P. Reeves joined Interface Biologics in November of 2008 as President and Chief Executive Officer. Tom brings a wealth of experience in running different companies in a variety of industries through various stages of growth. Most recently, he was President and COO of Occulogix, Inc. (NASDAQ: OCCX) a medical device company where he was instrumental in their Initial Public Offering raising over $100 million. Prior to OccuLogix, Mr. Reeves was the President of Borderfree, an international e-commerce service provider which was sold to Canada Post in 2004. Mr Reeves has also led Beamscope Canada Inc., Merisel Canada, Merisel Europe, and Merisel’s UK operation. Mr. Reeves started his career with the Boston Consulting Group (BCG) in San Francisco. He holds a BA in Economics, magna cum laude, from Harvard University and an MA in International Relations from the Australian National University.

Karen Greve Young, Vice President, Partnerships, MaRS Discovery District
MaRS achieves its mission to drive economic and social prosperity in partnership with fellow innovators and with the generous support of our funders. Karen Greve Young is MaRS’ executive lead responsible for facilitating and managing relationships with our global network of community, government and corporate partners. Karen joined MaRS in June 2011 as Director of Strategic Initiatives. Previously, she held management and strategy consulting roles in organizations in San Francisco, New York and London, UK, including Bain & Company, Gap Inc. and the UK’s Institute of Cancer Research. She has a personal interest in improving health outcomes, especially related to cancer. She holds a BA in Economics from Harvard University and an MBA from Stanford University’s Graduate School of Business, where she co-founded the student affiliate of the pro-bono Alumni Consulting Team.

Jennifer Zelmer, Executive Vice President, Canada Health Infoway
Dr. Zelmer leads Infoway’s clinical adoption, innovation and consumer health initiatives, as well as communications. She also has executive responsibility for Infoway’s relationship with Ontario. Prior to joining Canada Health Infoway, she held a series of progressively responsible leadership positions in Canada and abroad, most recently as Chief Executive Officer of the International Health Terminology Standards Organization (IHTSDO) in Copenhagen and with the Canadian Institute for Health Information. Dr. Zelmer received her PhD and her MA in economics from McMaster University and her B.Sc. in health information science from the University of Victoria. In addition to her role at Canada Health Infoway, she is the Editor-in-Chief of Healthcare Policy and is an Adjunct Faculty member at the University of Victoria, School of Health Information Science. Dr. Zelmer also serves on a range of health-related advisory committees and boards.

Have questions about Danish Innovation for Canadian Healthcare? Contact MaRS and the Royal Danish Consulate

When & Where

MaRS Discovery District, Auditorium
101 College Street West,
Toronto, Ontario

Thursday, September 18, 2014 from 10:00 AM to 2:00 PM (PDT)

  Add to my calendar

Interested in hosting your own event?

Join millions of people on Eventbrite.

Please log in or sign up

In order to purchase these tickets in installments, you'll need an Eventbrite account. Log in or sign up for a free account to continue.